BioInvent Reports Promising Data from Ongoing Phase 2a study for BI-1808 with KEYTRUDA(R) (pembrolizumab) in Recurrent Ovarian Cancer

24% ORR for BI-1808 combined with pembrolizumab represents a meaningful improvement over pembrolizumab monotherapy in recurrent ovarian cancer (8% ORR in KEYNOTE-100)The combination demonstrated a favorable safety and tolerability profileResults …